Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
QGEN 
Qiagen NV (QGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: QGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -24.41% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.54B USD | Price to earnings Ratio 103.95 | 1Y Target Price 49.8 |
Price to earnings Ratio 103.95 | 1Y Target Price 49.8 | ||
Volume (30-day avg) 1098685 | Beta 0.44 | 52 Weeks Range 37.63 - 47.96 | Updated Date 04/1/2025 |
52 Weeks Range 37.63 - 47.96 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 2.94% | Basic EPS (TTM) 0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.23% | Operating Margin (TTM) 27.66% |
Management Effectiveness
Return on Assets (TTM) 5.28% | Return on Equity (TTM) 2.27% |
Valuation
Trailing PE 103.95 | Forward PE 16.72 | Enterprise Value 8775109632 | Price to Sales(TTM) 4.39 |
Enterprise Value 8775109632 | Price to Sales(TTM) 4.39 | ||
Enterprise Value to Revenue 4.47 | Enterprise Value to EBITDA 24.03 | Shares Outstanding 216115008 | Shares Floating 214144306 |
Shares Outstanding 216115008 | Shares Floating 214144306 | ||
Percent Insiders 2.25 | Percent Institutions 62.15 |
Analyst Ratings
Rating 4 | Target Price 51.14 | Buy 4 | Strong Buy 7 |
Buy 4 | Strong Buy 7 | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Qiagen NV
Company Overview
History and Background
Qiagen NV was founded in 1984 in Du00fcsseldorf, Germany, initially focusing on innovative technologies for nucleic acid purification. It evolved from a small biotech startup to a global provider of sample and assay technologies for molecular testing. Key milestones include expansion into molecular diagnostics and automation.
Core Business Areas
- Sample Technologies: Provides solutions for extracting, purifying, and stabilizing DNA, RNA, and proteins from biological samples. This segment is fundamental to molecular testing workflows.
- Assay Technologies: Offers a wide range of assay kits and platforms for molecular diagnostics, applied testing, and research. Includes PCR, sequencing, and other molecular techniques.
- Bioinformatics: Provides software and databases for analyzing and interpreting biological data generated from sample and assay technologies. Helps researchers and clinicians make data-driven decisions.
Leadership and Structure
The leadership team consists of the CEO and other key executives responsible for different functional areas. The organizational structure is based on business units focused on sample technologies, assay technologies, and bioinformatics, with supporting functions like R&D, marketing, and operations.
Top Products and Market Share
Key Offerings
- QIAamp Kits: For DNA and RNA purification, used in research and diagnostics. High-quality nucleic acid extraction with competitors like Thermo Fisher Scientific and Roche. Estimated market share in nucleic acid extraction is around 20%.
- QuantiFERON-TB Gold Plus: An in-vitro diagnostic test for detecting latent tuberculosis infection. Leading market position in TB testing with competitors like Oxford Immunotec (TMO). Revenue is estimated to be above $250 Million USD per year.
- GeneReader NGS System: A next-generation sequencing platform for molecular diagnostics and research. Competitors include Illumina and Thermo Fisher Scientific. This segment of the NGS market is competitive and QIAGEN has not yet gained a major market share.
Market Dynamics
Industry Overview
The molecular diagnostics and life sciences industries are experiencing significant growth driven by increasing demand for personalized medicine, advancements in genomic technologies, and rising healthcare expenditures.
Positioning
Qiagen NV is a key player in the molecular diagnostics and life sciences market, positioned as a provider of integrated sample-to-insight solutions. Its competitive advantages include a broad portfolio of products, strong brand recognition, and a global presence.
Total Addressable Market (TAM)
The total addressable market for molecular diagnostics is estimated to be over $20 billion. Qiagen is well-positioned to capture a significant share of this market by leveraging its expertise in sample preparation, assay development, and bioinformatics.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Comprehensive product portfolio
- Global presence and distribution network
- Expertise in sample preparation and assay development
- Recurring revenue streams
Weaknesses
- Competition from larger players
- Pricing pressure
- Dependence on innovation
- Integration challenges with acquisitions
- Exposure to regulatory changes
Opportunities
- Expansion into emerging markets
- Development of new diagnostic tests
- Growth in personalized medicine
- Increased adoption of molecular diagnostics
- Partnerships and collaborations
Threats
- Technological disruptions
- Increased competition
- Regulatory hurdles
- Economic downturns
- Patent expirations
Competitors and Market Share
Key Competitors
- TMO
- ROSY
- ILMN
Competitive Landscape
Qiagen NV competes with larger players such as Thermo Fisher Scientific, Roche, and Illumina. Qiagen's advantages include a focus on sample preparation and a broad portfolio of diagnostic tests. Disadvantages include its smaller size and limited resources compared to its competitors.
Major Acquisitions
Exiqon
- Year: 2016
- Acquisition Price (USD millions): 160
- Strategic Rationale: Expanded Qiagen's capabilities in miRNA analysis and research.
NeuMoDx
- Year: 2020
- Acquisition Price (USD millions): 248
- Strategic Rationale: Expanded Qiagen's presence in automated molecular diagnostics.
Growth Trajectory and Initiatives
Historical Growth: Qiagen NV has demonstrated consistent growth over the past decade, driven by organic revenue growth and strategic acquisitions.
Future Projections: Analyst estimates project continued revenue growth for Qiagen NV, driven by demand for molecular diagnostics and personalized medicine.
Recent Initiatives: Recent strategic initiatives include investments in automation, expansion into new markets, and the development of new diagnostic tests.
Summary
Qiagen NV is a strong player in the molecular diagnostics market, focusing on sample preparation and assay technologies. The company has shown steady growth through organic initiatives and acquisitions. However, the competitive landscape is intense, requiring continuous innovation and adaptation. Future success relies on expanding into new markets and successful development of diagnostics.
Similar Companies
ILMN
Illumina Inc
ILMN
Illumina Inc
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Relations Materials
- Analyst Reports (e.g., from major investment banks)
- Industry Research Reports (e.g., from MarketWatch)
- Company press releases
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Actual results may vary. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qiagen NV
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-06-28 | CEO, MD & Member of Management Board Mr. Thierry Bernard | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 5700 | Website https://www.qiagen.com |
Full time employees 5700 | Website https://www.qiagen.com | ||
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, such as STR assays for human ID, and assays for food contamination; PCR instruments include digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It also offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI; and with Bio-Manguinhos/Fiocruz to detect malaria and dengue. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.